Small Cell Lung Cancer study: Alisertib
Official title A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06095505
What this study is testing
What is Alisertib?
This is an investigational pill being studied as a potential treatment for small cell lung cancer. It is designed to block a specific protein called GSK-3 that helps cancer cells grow and survive.
Also referred to as PB-8237, MLN8237.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether alisertib can help people with small cell lung cancer that has progressed after platinum chemotherapy and immunotherapy. It also looks at how safe the drug is and how it moves through the body.
- Who it's for
- You may be able to join if you have small cell lung cancer that has not worked with at least one platinum chemotherapy and one immunotherapy drug, and you have had no more than two prior cancer treatments.
- What's involved
- You would take alisertib by mouth at home. The study team will check your health with visits and tests to see how the drug works and if it causes side effects.
- Time commitment
- The study lasts about 6 months, with regular clinic visits and health checks during that time.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged ≥18 years at signing of informed consent
- Pathologically confirmed SCLC
- Prior treatment with one platinum-based chemotherapy and an anti-PD-L1/PD-1 immunotherapy.
You likely can't join if
- Prior treatment with an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting
- Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
The study team makes the final eligibility decision.
Where it is enrolling
- Daphne, Alabama, United States
- Long Beach, California, United States
- Lone Tree, Colorado, United States
- Washington D.C., District of Columbia, United States
- Clermont, Florida, United States
- Fort Lauderdale, Florida, United States
- Tampa, Florida, United States
- Niles, Illinois, United States
- Indianapolis, Indiana, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Burnsville, Minnesota, United States
- Grand Island, Nebraska, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
- Columbus, Ohio, United States
- Eugene, Oregon, United States
- Charleston, South Carolina, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Daphne, Alabama, United States; Long Beach, California, United States; Lone Tree, Colorado, United States; Washington D.C., District of Columbia, United States; Clermont, Florida, United States; Fort Lauderdale, Florida, United States and 18 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.